Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187545 | 0.80 | TSHR (0.41) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL2185729 | 0.80 | KMT2A (0.45) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL3263969 | 0.77 | APOBEC3G (0.40) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL1095240 | 0.77 | HIF1A (0.38) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL1126194 | 0.77 | KDM4E (0.44) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL30211545 | 0.74 | CA12 (0.46) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL27809179 | 0.74 | MEN1 (0.51) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL10910583 | 0.73 | CA12 (0.39) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL10911319 | 0.73 | KMT2A (0.36) | KMT2AMEN1CYP1A2POLBATM | |
| SCHEMBL1354417 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110168103-A | Reduce the method that primer dimer forms and improves amplification efficiency | SEEGENE株式会社 | 2019-08-23 | — | — | CN | claimed |
| CN-106399484-A | Double bubble shape fluorescence probe, applications thereof, and kit | 中国人民解放军第三军医大学第附属医院 | 2017-02-15 | — | — | CN | claimed |
| CN-105274096-A | Bridge type fluorescent probe with bridge type sequence zone doping into mismatched bases and application and method | UNIV PLA 3RD MILITARY MEDICAL | 2016-01-27 | — | — | CN | claimed |
| CN-101189336-B | Processes using dual specificity oligonucleotide and dual specificity oligonucleotide | SEEGENE INC | 2012-10-24 | — | — | CN | claimed |
| CN-110168103-A | Reduce the method that primer dimer forms and improves amplification efficiency | SEEGENE株式会社 | 2019-08-23 | — | — | CN | disclosed |
| CN-106399484-A | Double bubble shape fluorescence probe, applications thereof, and kit | 中国人民解放军第三军医大学第附属医院 | 2017-02-15 | — | — | CN | disclosed |
| CN-105274096-A | Bridge type fluorescent probe with bridge type sequence zone doping into mismatched bases and application and method | UNIV PLA 3RD MILITARY MEDICAL | 2016-01-27 | — | — | CN | disclosed |
| CN-102782150-B | Target detection of target hybrid and detection primer | SEEGENE INC | 2015-04-01 | — | — | CN | disclosed |
| CN-103228797-A | Detection of target nucleic acid sequences using dual-abeled immobilized probes on solid phase | SEEGENE INC | 2013-07-31 | — | — | CN | disclosed |
| CN-1578841-B | Annealing control primer and use of the same | VISION GENE CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-102782150-A | THD primer target detection | SEEGENE INC | 2012-11-14 | — | — | CN | disclosed |
| CN-102770556-A | Targeted probes and uses thereof | SEEGENE INC | 2012-11-07 | — | — | CN | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| WO-2008113456-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND USE OF SAME FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
| CN-1578841-A | Annealing control primer and use of the same | VISION GENE CO LTD (KR) | 2005-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | KMT2A 1675/4885MEN1 1598/4885CYP1A2 4804/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | KMT2A 1350/4885MEN1 4796/4885CYP1A2 4840/4885 |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | LDLR, RNASE1, SARNP | KMT2A 2199/4885MEN1 1035/4885CYP1A2 4515/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | KMT2A 1569/4885MEN1 939/4885CYP1A2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.